Streetbeat News

Regulatory

MT

The U.S. Department of Energy has announced financial support for ArcelorMittal's electrical steel facility in Alabama, awarding the company $280.5 million in investment tax credits from the IRS.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:24 pm

MLEC

Shares of Moolec Science SA (NASDAQ:MLEC) surged after announcing USDA-APHIS approval for its genetically engineered soybean, Piggy Sooy, which produces animal meat protein. This marks a significant biotechnological milestone, as it's the first product of its kind to receive such approval, indicating it does not pose an increased plant pest risk. The company previously reported high levels of pork protein expression in Piggy Sooy seeds and has patented the technology.

Portfolio Pulse from Shivani Kumaresan

April 22, 2024 | 12:22 pm

EEIQ

EpicQuest Education Group International Ltd (EEIQ) announced that its EduGlobal College has received approval for two new co-op programs, significantly expanding its academic offerings. The PTIB-approved programs have tripled, and all academic programs have seen a 50% increase.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:18 pm

LTRN

Lantern Pharma has received approval to expand its Harmonic clinical trial for non-small cell lung cancer in never-smokers into Japan and Taiwan, with Dr. Yashushi Goto of the National Cancer Center of Japan as a lead investigator.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:13 pm

PFE

The European Commission has granted approval to Pfizer's EMBLAVEO, a β-lactam/β-lactamase inhibitor antibiotic combination, for treating serious infections in adults caused by multidrug-resistant Gram-negative bacteria. This marks the first approval of its kind in the European Union, specifically targeting infections with limited treatment options, including those caused by metallo-β-lactamase-producing bacteria. EMBLAVEO was expedited through the European Medicines Agency's accelerated assessment procedure, highlighting its significance for public health and therapeutic innovation.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:10 pm

AAPL

Pavel Durov, the founder of Telegram Messenger, criticized Apple Inc.'s App Store policies, predicting a decline in iPhone market share in China. He highlighted the Chinese government's encouragement for citizens to switch to Android smartphones, like those made by Xiaomi and Huawei, due to Apple's restrictive app installation policies. Despite Apple's recent concessions in the EU, its strict App Store rules, including the removal of apps like Telegram and Meta Platforms Inc.'s WhatsApp and Threads under Chinese government pressure, could further diminish its market share in China.

Portfolio Pulse from Rounak Jain

April 22, 2024 | 12:08 pm

FRES

Fresh2 Group Ltd. (NASDAQ:FRES), a B2B e-commerce and supply chain management company in the food industry, received a delinquency notice from Nasdaq for not filing its Annual Report on time. The company has 60 days to submit a compliance plan to avoid delisting.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:05 pm

ORCL

Oracle has received accreditation for three cloud regions to host U.S. Department of Defense (DoD) secret classified workloads, achieving Defense Information Systems Agency Impact Level 6 Authorization. This positions Oracle's cloud as a high-performance, cost-effective solution for classified defense workloads.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:04 pm

ADIL

Adial Pharmaceuticals Inc (NASDAQ:ADIL) has been granted a US patent (number 11957664) for a combination of its proprietary genetic diagnostic and its lead investigational drug, AD04, for treating alcohol use disorder (AUD) and other drug dependencies such as opioid use disorder (OUD). This patent strengthens Adial's intellectual property portfolio, covering specific genotypes for targeted treatment. The addressable market for these treatments in the U.S. is estimated at $40 billion. Additionally, Adial has previously received a patent for AD04 targeting the serotonin transporter gene for potential OUD treatment and published positive clinical results and safety profiles for AD04.

Portfolio Pulse from Vandana Singh

April 22, 2024 | 12:00 pm

ADIL

Adial Therapeutics has been granted a key patent from the United States Patent and Trademark Office, according to an exclusive report by Benzinga. This development could potentially enhance the company's intellectual property portfolio and strengthen its position in its respective market.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 12:00 pm